Nymox Pharmaceutical Corporation cash flow statement NYMXF
In fiscal 2024, which ended Dec 31, 2024, Nymox Pharmaceutical Corporation used $2.6 million of cash from operations, up 35.9% from the year before. It spent $0 on capital expenditures. Free cash flow was negative, at -$2.6 million.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
|---|---|---|---|---|---|---|---|---|
| Operating | ||||||||
| Operating cash flow |
-3
+35.9%
|
-4
+22.1%
|
-5
+47.0%
|
-10
+2.2%
|
-10
-35.1%
|
-7
+4.8%
|
-8
-25.7%
|
-6
|
| Investing | ||||||||
| Capital expenditures |
0
-100.0%
|
0
|
—
|
—
|
0
-63.9%
|
—
|
0
+1700.0%
|
—
|
| Investing cash flow |
0
+100.0%
|
-0
|
0
+100.0%
|
-0
+53.8%
|
-0
+63.9%
|
—
|
-0
|
—
|
| Financing | ||||||||
| Debt issued |
3
+52.5%
|
2
|
—
|
—
|
—
|
—
|
—
|
—
|
| Financing cash flow |
3
-4.5%
|
3
-52.8%
|
6
-18.0%
|
7
-16.4%
|
8
+78.3%
|
5
-68.4%
|
15
+196.3%
|
5
|
| Change in cash | ||||||||
| Effect of exchange rate |
0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Net change in cash |
0
+100.3%
|
-1
-332.6%
|
1
+120.6%
|
-3
-70.8%
|
-2
+39.9%
|
-3
-138.2%
|
7
+708.0%
|
-1
|
| Free cash flow |
-3
+35.9%
|
-4
|
—
|
—
|
-10
-34.6%
|
—
|
-8
-26.2%
|
—
|
| Ratios | ||||||||
| Free cash flow margin |
—
|
—
|
—
|
—
|
-201,000.00%
|
—
|
-2,621.07%
|
—
|
| Capital expenditures to revenue |
—
|
—
|
—
|
—
|
260.00%
|
—
|
12.04%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NYMXF (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Quebec Canada, Quebec, Canada
- SEC filer status
- Accelerated filer
- SEC CIK
- 1018735
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.